Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open
KalVista Pharmaceuticals announced plans to soon begin enrolling patients in KOMPLETE, a Phase 2 clinical trial testing its investigational oral therapy KVD824 in preventing swelling attacks in people with hereditary angioedema (HAE) at sites in Canada, Australia, and the U.K. “Over the past month we have made substantial progress in…